Skip to main content

MoneyWorks4Me

Clarification sought from Glenmark Pharmaceuticals

30 Oct 2015 Evaluate

The Exchange has sought clarification from Glenmark Pharmaceuticals with reference to news reported on CNBC TV18 on October 29, 2015 -‘Setback For Glenmark: Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1768.40
Dr. Reddys Labs. 1353.40
Cipla 1383.80
Lupin 2002.95
Zydus Lifesciences 1240.80
View more..